Press release
August 14, 2026
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics Inc. (HCWB)
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia,